Structural highlights
Publication Abstract from PubMed
Since the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed have been implemented at industrial scale and are seminal for the supply of human insulin and insulin analogues to people with diabetes now and in the future. Engineering of a target protein with removable structural elements may provide a general approach to yield optimisation.
Molecular engineering of insulin for recombinant expression in yeast.,Kjeldsen T, Andersen AS, Hubalek F, Johansson E, Kreiner FF, Schluckebier G, Kurtzhals P Trends Biotechnol. 2024 Apr;42(4):464-478. doi: 10.1016/j.tibtech.2023.09.012. , Epub 2023 Oct 24. PMID:37880066[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Kjeldsen T, Andersen AS, Hubálek F, Johansson E, Kreiner FF, Schluckebier G, Kurtzhals P. Molecular engineering of insulin for recombinant expression in yeast. Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. PMID:37880066 doi:10.1016/j.tibtech.2023.09.012
